Friday, 16 Feb 2018

You are here

Denosumab Increases Trabecular Bone

Bone mineral density (BMD) measurement vie DEXA scan commonly used to assess bone density and fracture risk in postmenopausal osteoporosis provides us with approximate assessment of bone health while lacking sensitivity in vertebral fracture risk prediction. Newer techniques, such as the trabecular bone score (TBS), provide better insight into bone microarchitecture - an important factor for fragility fracture.

TBS has been shown to be predictive of fragility fractures in postmenopausal women with primary osteoporosis and has been newly included in international guidelines, providing an additional screening tool to identify patients in need of therapeutic intervention.

Assuming TBS may have a better predictive value in future fracture preventions, this retrospective review of the 3 –year long FREEDOM trial was designed to explore the effect of denosumab on TBS and association between TBS and BMD in 7808 postmenopausal women with osteoporosis in FREEDOM cohort.

Using TBS iNsight software in a blinded-to-treatment manner, the TBS of subjects who participated in the DXA substudy was determined retrospectively. 285 patients were established to have measurable TBS at baseline and were included in analysis.

In the denosumab group, progressive statistically significant increase from baseline at 12/24/26 months was observed for both BMD (5.7/7.8/ 9.8%, respectively) and TBS (1.4/1.9/ 2.4%), p value p<0.001.

More subjects in the denosumab group than in the placebo group had TBS gains of 5.82% or greater at 12 months (15 vs 11%; p = 0.271), 24 months (21 vs 9%; p = 0.012), and 36 months (20 vs 6%; p = 0.001).

There was no significant correlation between TBS and BMD in this study, which in author’s opinion supports the principle that TBS provides a measure of bone not captured by standard densitometric techniques and may allow for an improved assessment of differences in responses to diverse therapies for osteoporosis.

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I would encourage the title of this segment to be that Denosumab increases Trabecular Bone Score. No anti-resorptive can actually increase bone mass. BMD and in a complex way TBS assesses bone mineral and in the case of TBS, the pattern of distribution. Anti-resorptive drugs decrease bone remodeling and more mineral goes into the stable bone mass. More mineral may alter the BMC and also the edge detection of the interface between bone and soft tissue. Clearly BMD and TBS can increase but bone mass does not increase. I urge readers to look at paired biopsy studies.

More Like This

Teriparatide Superior to Risedronate in the VERO Trial

Lancet reports that in a study teriparatide with risedronate, post-menopausal women with severe osteoporosis had significantly fewer new vertebral and clinical fractures on teriparatide comared to those receiving risedronate.

This trial is one of the first to compare osteoporosis drugs with incident fractures as the primary outcome.

Two Types of Osteoarthritis Based on Cartilage Studies

A report from Annals of Rheumatic Diseases suggests that osteoarthritis (OA) may be two distinct diseases based on genetic studies of articular cartilage. (Citation source:

RNA sequencing of knee cartilage from 44 OA patients undergoing total knee replacement was compared to 6 additional patients with OA and 10 control patients with non-OA.

New Rise in Hip Fractures Amongst Women

Reuters reports that the incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients.

Calcium and Vitamin D Supplements Do Not Reduce Hip Fractures

Recent JAMA study shows metanalysis of 33 clinical trials and 51,145 participants, showed that calcium, vitamin D, or both affords no decreased risk of hip fractures compared with placebo or no treatment and therefore questions their routine widespread use in the elderly.. 

Community Screening for Fracture Risk in Older Women is Effective and Feasible

A UK Study published in Lancet shows that community-based screening programme for fracture risk in older women is feasible, and may reduce hip fractures. 

Older women, age 70-85 yrs, were identified and participated in the trial and were assessed using the Fracture Risk Assessment Tool (FRAX) with usual management. 12 483 were enrolled and 6233 women randomly assigned to the screening group.